Micraleve

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Micraleve

Property Description
Active ingredient Mitoxantrone hydrochloride (Mitoxantrone)
Form Concentrate for solution for infusion
Pharmacological class Antineoplastic Agent, Immunosuppressant
General purpose Targets rapidly dividing cells and modulates immune function
Origin Synthetic (Anthracenedione derivative)

Micraleve: Definition and Pharmacological Classification

Micraleve is a highly specialized treatment used in systemic therapy, whose core component is the active ingredient Mitoxantrone (INN). The drug is formally classified by medical bodies as both a powerful Antineoplastic Agent and an Immunosuppressant, a dual pharmacological role clinically recognized for its therapeutic significance. This medication belongs to the synthetic anthracenedione derivative class, distinguishing it chemically from older cytotoxic agents. The compound’s molecular structure allows it to provide targeted action, which is a key differentiating factor from general, non-specific chemotherapeutic approaches.

Composition and Pharmaceutical Form

The medication is a single-agent product supplied as a concentrate for solution for infusion, which is a sterile, aqueous liquid containing Mitoxantrone hydrochloride. This specific pharmaceutical preparation is strictly intended for intravenous (IV) administration directly into the bloodstream. This route of administration is essential for ensuring the medicine's immediate and comprehensive distribution throughout the body, supporting its critical role as a systemic therapy.

General Purpose and Therapeutic Application

The general purpose of Micraleve is to provide a comprehensive means of controlling or eliminating the activity of problematic cells by its mechanism of effect as a potent topoisomerase II inhibitor. This established action causes the targeted disruption of DNA replication and repair within fast-growing cells. Furthermore, the drug is utilized for its significant immunomodulation benefit, which allows it to help manage inflammatory activity by dampening certain immune cell responses.

Regulatory References

  1. NCI Drug Dictionary Definition

What side effects are possible with Micraleve?

The safety profile of Micraleve, which contains the active ingredient Mitoxantrone, reflects its classification as a potent antineoplastic and immunosuppressive agent. All documented adverse reactions and safety statements are based strictly on official government regulatory labeling.

Serious Adverse Reactions and System-Organ Effects

The official safety information highlights the risk of dose-limiting myelosuppression (severe reduction in blood cell counts), which is typically reversible with the nadir occurring 10 to 14 days after dosing. The most critical risk is cardiac toxicity, which includes the potential for developing irreversible congestive heart failure (CHF) and cardiomyopathy.

The risk of cardiac damage is directly associated with the cumulative lifetime dose received, and these serious effects can occur months to years after treatment is completed. Treatment also carries a rare but documented risk of secondary malignancies, specifically Acute Myeloid Leukemia (AML).

Common Adverse Effects and Classifications

Adverse effects commonly documented in regulatory labeling (classified as Very Common, affecting more than 1 in 10 people) involve the Blood and Lymphatic System Disorders (e.g., leukopenia, anemia) and Gastrointestinal Disorders (e.g., nausea and vomiting). Other very common effects include infections and alopecia (hair loss).

Temporary and harmless blue-green discoloration of the urine and sclera (whites of the eyes) is also a documented event. The drug is generally not recommended for patients with a baseline neutrophil count below 1,500 cells/ mm^3 or those with pre-existing heart or severe hepatic impairment.

Population-Specific Safety

Safety considerations apply to specific patient groups: those with reduced left ventricular ejection fraction (LVEF) face an increased risk of cardiotoxicity, and patients with hepatic impairment may experience reduced drug clearance, leading to increased systemic exposure. The label advises particular caution in pediatric patients due to the risk of delayed cardiotoxicity.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory documents define the overdose profile for Micraleve (Mitoxantrone) by its potential for severe, life-threatening damage to the hematopoietic and cardiovascular systems.

Documented Overdose Manifestations

  • Severe myelosuppression, including neutropenia and thrombocytopenia, represents a principal manifestation of overexposure.
  • Life-threatening cardiotoxicity is a documented risk, including decreases in Left Ventricular Ejection Fraction (LVEF) and the potential for fatal congestive heart failure.
  • The severity of toxic manifestations, particularly myelosuppression, is generally dose-dependent.

Required Emergency Action

Immediate medical attention must be sought for suspected or confirmed overexposure. Overdose has been reported with fatal outcomes, and the risk of severe, delayed, and potentially fatal complications mandates urgent, specialized care.

The official labeling states that no specific antidote is known for Mitoxantrone overdose.

Management consists of symptomatic and supportive treatment, requiring continuous hospital observation and specialized monitoring.

Monitoring includes frequent peripheral blood cell counts (CBCs) and continuous cardiac function monitoring (ECG, LVEF assessment) due to the risk of late-onset toxicity.

Patients with pre-existing cardiac impairment or impaired hepatic function are noted to have an increased risk for severe toxic effects following overexposure.

Therapeutic Uses of Micraleve

Micraleve, a brand name for a combination product, is generally indicated for the short-term symptomatic relief associated with migraine attacks.


What Micraleve Treats: Main Uses and Benefits

Micraleve is intended to provide acute symptomatic relief for moderate migraine pain in circumstances where non-opioid analgesics alone may not be adequate. Its components are formulated to address the complex manifestations of a migraine episode, specifically the headache and the often associated feelings of nausea and vomiting.

The product's intended uses align with the need for short-term assistance with acute moderate pain, such as that experienced during migraine attacks. This therapeutic application is focused on the short-term treatment of acute moderate pain associated with such episodes.

This combination formulation is intended to offer symptomatic support across two categories: pain reduction (for the moderate headache) and mitigation of associated nausea and vomiting (for the accompanying anti-sickness symptoms).

Quick Fact: Relief for Moderate Migraine Pain and Associated Nausea

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Micraleve (Mitoxantrone) — Official Regulatory Information

Eligibility Scope

Classification Status According to Regulatory Documents
Populations for whom use is allowed Adults with specific forms of Multiple Sclerosis (secondary progressive, progressive-relapsing, or worsening relapsing-remitting), Acute Nonlymphocytic Leukemia (ANLL), and advanced hormone-refractory prostate cancer.
Populations for whom use is contraindicated Patients with prior hypersensitivity to the drug; women who are pregnant or breastfeeding; and MS patients with a baseline Left Ventricular Ejection Fraction (LVEF) below the lower limit of normal.
Populations for whom use is not recommended Generally, patients with baseline neutrophil counts of less than 1,500 cells/ mm^3 (except for ANLL) or those with severe hepatic impairment.

Age and Condition-Specific Eligibility Rules

  • Age-related eligibility rules: Use is established only in adults (Age 18 years). Safety and efficacy have not been established in pediatric patients. Use in older adults requires increased caution due to age-related changes in organ function.
  • Pregnancy and lactation eligibility status: Contraindicated in both states; female patients of childbearing potential must use effective contraception, and a negative pregnancy test is required before each dose for MS patients.
  • Eligibility-related restrictions: Eligibility is limited by a maximum lifetime cumulative dose (e.g., 140 mg/m^2) and is conditional on avoiding treatment if the patient has not recovered from severe myelosuppression due to previous therapy.

Connection to the overall eligibility profile: The official eligibility profile is strictly defined by mandated maximum lifetime exposure limits and stringent baseline functional requirements for the patient's heart and bone marrow. Regulatory documents enforce non-eligibility through absolute contraindications and conditional restrictions based on the status of key organs, ensuring use is strictly limited to officially recognized adult populations and specific disease subtypes.

What should I know about interactions with other medicines?

The official interaction profile of the active ingredient, Mitoxantrone, is defined by documented risks of toxicity reinforcement and alteration of systemic drug exposure.

Documented Pharmacological Interactions

Classification Interacting Agents / Conditions
Toxicity Reinforcement Cardiotoxic Drugs (e.g., Doxorubicin, Epirubicin) and other Myelosuppressive/Cytotoxic Agents
Exposure Modification Inhibitors or inducers of efflux transporters, specifically BCRP (Breast Cancer Resistance Protein) and P-glycoprotein (P-gp).

Interaction-Related Constraints

The regulatory label for Mitoxantrone establishes specific constraints:

  • Procedural Prohibition: The drug must not be mixed in the same intravenous infusion with Heparin due to the risk of precipitate formation.
  • Pharmacodynamic Prohibition: Co-administration with Live Vaccines is contraindicated due to the risk of diminished vaccine efficacy from the drug's immunosuppressive action.
  • Population Note: Clearance of Mitoxantrone is formally documented to be reduced by hepatic impairment. Patients with severe dysfunction can experience an AUC more than three times greater than those with normal hepatic function, requiring recognition of altered systemic exposure.

Regulatory documents highlight that concurrent use with other cardiotoxic or myelosuppressive agents is officially noted to result in the additive reinforcement of those risks, which defines the core safety structure of the interaction profile.

Mechanism of Action

Core Molecular Mechanism: DNA Disruption and Topoisomerase II Inhibition

Micraleve (Mitoxantrone) initiates its action by functioning as a DNA intercalator and a Topoisomerase II inhibitor. This dual mechanism physically inserts the molecule between DNA base pairs and prevents the re-ligation of cleaved DNA strands, leading to unrepairable double-strand breaks. The resulting genotoxic stress triggers the cell's internal process of programmed death (apoptosis), producing a fundamental cytotoxic and anti-proliferative consequence for susceptible cell populations.


️ Systemic Immunomodulation via Selective Cell Depletion

The cytotoxic mechanism mediates systemic immunomodulation by acting preferentially on high-turnover components of the immune system, specifically T-lymphocytes and B-lymphocytes. This results in a numerical and functional depletion of these cell populations, accompanied by a suppression of the release of pro-inflammatory mediators. The physiological consequence is a reduction in the intensity of cellular immune responses across systemic compartments.


Mechanistic Constraint and Indirect CNS Action

A key mechanistic constraint is the drug's limited penetration of the intact Blood-Brain Barrier (BBB). Its influence on CNS-related physiological processes is therefore indirect, resulting from its action on peripheral immune cells and inflammatory factors, which reduces their capacity for CNS compartment infiltration. This systemic modulation of immune activity occurs independently of direct, high drug concentrations within the CNS parenchyma.

Dosage and Administration Information

How Micraleve is Used: Official Administration Guidelines

Micraleve (Mitoxantrone) is strictly administered under specialist supervision and follows specific, label-defined protocols governing its delivery, preparation, and scheduling.


Administration Scope

Category Official Instruction
Route of Administration Strictly intravenous (IV) infusion only. Administration by any other route (e.g., subcutaneous, intrathecal) is forbidden.
Standard Dosing The dose is calculated based on the patient's body surface area ( mg/m^2). For Multiple Sclerosis (MS), the dose is 12 mg/m^2, while certain leukemia induction regimens may use 12 mg/m^2 daily for two to three days.
Frequency Pattern Usage is either intermittent (e.g., quarterly for MS) or cyclic (e.g., consecutive daily doses followed by a rest period for chemotherapy).
Preparation The 2 mg/mL concentrate must be diluted prior to infusion using at least 50 mL of 0.9% Sodium Chloride or 5% Dextrose injection solution.

Procedural and Course Constraints

The preparation and delivery process must be performed by a professional and adhere to a controlled sequence. The diluted solution is administered as a short intravenous infusion over a period typically lasting 5 to 15 minutes. Crucially, a maximum cumulative lifetime dose of 140 mg/m^2 is established for treatment, which governs the total duration of therapy. Dosage modification is required for patients with impaired liver function, as specified by their serum bilirubin levels. This regulated procedural structure ensures the medicine is used in accordance with the established government guidelines.

Recent Clinical Evidence

Evidence for Use in Active, Worsening Multiple Sclerosis (MS)

Research for the active ingredient Mitoxantrone was studied for its use in certain forms of Multiple Sclerosis (MS), including worsening Relapsing-Remitting and Secondary Progressive types. Randomized Controlled Trials (RCTs) were used in research exploring how symptoms change over time in adult patients. Researchers focused on outcomes related to systemic or functional imbalance, such as the frequency of relapses and the pace of disability progression. Trials reported measurements of the change in the rate of disability accumulation and changes in the Annual Relapse Rate. However, long-term effects are not fully established because the initial pivotal trials typically had limited follow-up durations.


Evidence for Use in Acute Leukemias (AML and ANLL)

The agent was observed in various clinical studies focused on Acute Leukemias, such as Acute Myeloid Leukemia (AML). These studies included children, adolescents, and adults. The primary outcomes examined were the Complete Remission (CR) rate and various Overall Survival (OS) metrics. Studies explored the rate of achieving remission when the agent was used as part of multi-drug chemotherapy protocols. Comparative evidence is lacking for its use as a single agent versus its role within combination regimens, which is the primary setting documented. Evidence quality varies across studies, and certainty remains low when isolating the specific contribution of the agent outside of combination treatment.


Evidence for Use in Palliative Cancer Treatment

The agent was studied for its role in the palliative treatment of symptoms related to Advanced Cancers, such as specific types of Castrate-Resistant Prostate Cancer (CRPC). Research examined the effects of the treatment, focusing on outcomes related to physical discomfort and patient-reported outcomes describing perceived discomfort. Trials reported measurements of lower pain scores and changes in the need for analgesic medication in the treatment groups. Findings indicate that no measurable difference in the Overall Survival endpoint was observed when comparing the treated group to the control groups in key trials. Follow-up durations were limited, focusing mainly on short-term symptom changes.


Research Gaps and Uncertainties

Evidence highlights what is known—and what is still uncertain—about this agent. The main limitations in the research record are related to long-term effects after treatment, which are not fully established across all indications. For the leukemia treatment, research is derived primarily from combination therapy studies, and data for certain groups remain insufficient. Study results reflect the specific conditions under which they were conducted, and research does not determine whether an individual will respond similarly.

Frequently Asked Questions (FAQ)

Common questions about Micraleve (FAQ)

Q: Does Micraleve cause weight gain or weight loss?

Official reports from clinical studies indicate that changes in body weight, including both weight gain and weight loss, have been reported as potential side effects. The incidence of these weight changes can vary depending on the specific condition being treated, according to the official product information.


Q: Is it common to feel tired after taking Micraleve?

Regulatory documents indicate that fatigue, characterized by feelings of tiredness or weakness, is a commonly reported side effect associated with this medication. Official product information reflects that this is a commonly documented adverse reaction.


Q: Can Micraleve affect my mood or sleep?

Official safety information includes reports of Central Nervous System (CNS) effects. These have included descriptions of anxiety, depression, confusion, and feelings of drowsiness.


Q: Does Micraleve interact with common over-the-counter medicines like ibuprofen or Tylenol (acetaminophen)?

Regulatory documents describe the risk of combined use with other medicines that may suppress bone marrow activity (myelosuppressive agents). Specifically, official information notes that the metabolism of acetaminophen may be altered when combined with mitoxantrone. The regulatory interaction profile does not provide specific guidance on ibuprofen.


Q: Can Micraleve be taken with blood pressure medication?

Micraleve is described as a cardiotoxic agent, meaning it carries a risk of potentially affecting the heart. Official guidance therefore describes a need for caution when the drug is used alongside other medicines known to carry a risk of cardiotoxicity. The patient’s cardiac function is assessed throughout the course of treatment.


Q: What types of food or drinks should I avoid while using Micraleve?

Official regulatory product information does not document specific mandatory restrictions concerning food or drinks. The lack of documented restrictions means there is no formal food-drug interaction warning in the official label.


Q: What if I have kidney problems; can I still use Micraleve?

Official documents note that use in patients with renal impairment (kidney function) is not typically associated with specific dosage modification requirements. However, the use of the drug is generally discouraged or contraindicated in cases of severe hepatic impairment (liver problems).


Q: How long does Micraleve stay in your system?

Mitoxantrone, the active ingredient, is eliminated slowly from the body. Regulatory pharmacokinetics data indicates a long and variable half-life, which can range from 23 to 215 hours. The elimination process may be prolonged in individuals who have impaired liver function.


Q: Where can I find the official prescribing information for Micraleve?

The complete and official prescribing details can be accessed through governmental drug databases. Examples include the U.S. FDA DailyMed and the European Medicines Agency (EMA) Summary of Product Characteristics (SmPC).


Q: Are there generic versions of Micraleve available?

Yes, the patent protection for the active ingredient in Micraleve, mitoxantrone hydrochloride, has expired in many regions. As a result, several regulatory bodies have approved generic versions of the drug.


Q: Can Micraleve cause a tingling sensation?

Official patient information reports nerve damage, characterized by tingling, numbness, or prickling (a condition called paresthesia), as a documented side effect. This type of effect is listed in official documents as a rare side effect.


Q: What are the signs of a severe allergic reaction to Micraleve?

The occurrence of a severe allergic reaction (hypersensitivity) is rare. Official safety information indicates possible signs can include sudden difficulty breathing, swelling of the face, throat, or limbs, a sudden itchy rash (hives), or feeling faint. Hypersensitivity to the drug is listed as a formal contraindication.


Q: Does Micraleve contain any common allergens like gluten or lactose?

The regulatory labeling notes that the formulation contains sodium metabisulfite, which is a sulfite. Sulfites contain a sulfite which may be associated with allergic-type reactions in sensitive individuals, such as those with asthma. A full list of all non-active ingredients (excipients) is available in the official labeling.


Q: Can Micraleve affect my ability to drive or operate machinery?

Official documents indicate that side effects such as fatigue and Central Nervous System (CNS) effects, including drowsiness or confusion, have been reported. If a patient experiences such effects, their ability to safely drive or operate complex machinery may be impaired.

How should Micraleve be stored and disposed of?

Official Storage and Disposal Requirements for Micraleve

The official labeling for Micraleve (Migraleve) provides specific instructions to ensure product stability and safety, strictly according to regulatory documents.

Requirement Area Regulatory Statement
Storage Temperature Do not store above 30 C.
Shelf-Life The shelf life is 3 years; do not use after the expiry date on the carton.
Child Protection Keep out of the sight and reach of children. The packaging includes child-resistant blister lidding.
Packaging Keep the tablets in the original blister packaging.
Disposal Do not dispose of unused or expired medicine via wastewater or household waste. Consult a pharmacist for proper disposal methods, which helps protect the environment and complies with local requirements.

These official rules define the product's storage environment and mandate specific steps for disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Micraleve found in:

A-Z Index: